Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones

Year 2018, , 320 - 325, 04.10.2018

Tayfun Şahinkanat , Erkan Efe , Hasan Çetin Ekerbiçer , Faruk Küçükdurmaz

https://doi.org/10.18621/eurj.349721

Abstract

Objectives:
Although there are several studies addressing the efficacy of phosphodiesterase
type 5 inhibitors for the management of benign prostatic hyperplasia-lower
urinary tract symptoms (BPH-LUTS), unfortunately, there is a lack of high
evidence data to support their effect at the prostate level. The existing
studies suggested that resistive index (RI) could be used as a hemodynamic
parameter to measure the severity of benign prostatic hyperplasia and
intraprostatic pressure or bladder outlet obstruction. The aim of this study
was to evaluate the effect of a single dose 20 mg tadalafil on resistive index
value in prostate zones to evaluate the mechanism of action of
phosphodiesterase type 5-inhibitors at the prostate level.

Methods: Twenty consecutive patients
aged between 54-67 years with BPH-LUTS [International Prostate Symptom Score ≥ 12]
and erectile dysfunction [five-item International Index of Erectile Function
(IIEF) questionnaire < 22] underwent RI measurement in prostate transitional
zone (TZ) and peripheral zone (PZ) using transrectal power Doppler
ultrasonography baseline and within 16 hours after the administration of 20 mg
tadalafil. The primary study end point is the change in prostate TZ RI values.

Results: The mean baseline total
prostate scores and peak urinary flow were 16.2 ± 4.34 (range: 12-26) and 10.45
ml/s (range: 7-13 ml/s), respectively. The mean baseline total IIEF was 12.8 ± 4.22
(range: 6-20). The mean TZ RI at baseline and after tadalafil administration
were 0.4985 and 0.5497, respectively (p
= 0.232). No statistically significant differences for RI changes between
baseline and after the administration of a single dose 20 mg tadalafil were
observed in the prostatic zones.

Conclusion:
A single dose 20 mg tadalafil showed no impact on prostate TZ RI. 

Keywords

tadalafil, prostate, phosphodiesterase type 5 inhibitors, resistive index, erectile dysfunction

References

• [1] Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
• [2] Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
• [3] McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
• [4] McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7.
• [5] Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502-7.
• [6] Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259-63.
• [7] Waldkirch ES, Uckert S, Langnase K Richter K, Jonas U, Wolf G, et al. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007;52:495-501.
• [8] Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007;69:25-6.
• [9] Yencilek E, Koyuncu H, Arslan D, Bastug Y. The measurement of the prostatic resistive index is a reliable ultrasonographic tool to stratify symptoms of patients with benign prosthatic hyperplasia. Med Ultrason 2014;16:208-13.
• [10] Zhang X, Li G, Wei X, Mo X, Hu L, Zha Y, et al. Resistive index of prostate capsular arteries: a newly identified parameter to diagnose and assess bladder outlet obstruction in patients with benign prostatic hyperplasia. J Urol 2012;188:881-7.
• [11] Kojima M, Ochiai A, Naya Y, Okihara K, Ukimura O, Miki T. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol 2000;37:436-42.
• [12] Tsuru N, Kurita Y, Masuda H, Suzuki K, Fujita K. Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 2002;9:427-30.
• [13] Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, Kaminetsky J, et al. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology 2014;84: 412-20.
• [14] Bertolotto M, Trincia E, Zappetti R, Bernich R, Savoca G, Cova MA. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrastenhanced US. Radiol Med 2009;114:1106-14.
• [15] Haaga JR, Exner A, Fei B, Seftel A. Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil. Int J Impot Res 2007;19:110-3.
• [16] Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005;96:1073-8.
• [17] Kojima M, Watanabe H, Watanabe M, Okihara K, Naya Y, Ukimura O. Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol 1997;23:1305-9.
• [18] Abdelwahab O, El-Barky E, Khalil MM, Kamar A. Evaluation of the resistive index of prostatic blood flow in benign prostatic hyperplasia. Int Braz J Urol 2012;38:250-5.
• [19] Özden C, Günay I, Deren T, Bulut S, Koparal S, Memiş A. Effect of doxazosin on prostatic resistive index in patients with benign prostatic hyperplasia. Fırat Tıp Dergisi 2009;14:171-4.
• [20] Ozden C, Gunay I, Deren T, Bulut S, Ozdal OL, Koparal S, et al. Effect of transurethral resection of prostate on prostatic resistive index. Urol Int 2010;84:191-3.
• [21] Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combinationwith α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.